Bone Biologics Corporation
BBLG
$0.6899
$0.02393.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.09M | 2.35M | 2.34M | 2.62M | 2.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.22M | 3.82M | 4.95M | 7.18M | 9.43M |
| Operating Income | -4.22M | -3.82M | -4.95M | -7.18M | -9.43M |
| Income Before Tax | -4.11M | -4.14M | -5.12M | -6.10M | -8.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.11 | -4.14 | -5.12 | -6.10 | -8.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.11M | -4.14M | -5.12M | -6.10M | -8.95M |
| EBIT | -4.22M | -3.82M | -4.95M | -7.18M | -9.43M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.96 | -7.73 | -10.26 | -14.80 | -68.69 |
| Normalized Basic EPS | -1.96 | -3.12 | -5.85 | -8.69 | -42.36 |
| EPS Diluted | -4.96 | -7.73 | -10.26 | -14.80 | -68.69 |
| Normalized Diluted EPS | -1.96 | -3.12 | -5.85 | -8.69 | -42.36 |
| Average Basic Shares Outstanding | 6.06M | 4.04M | 2.68M | 1.85M | 1.26M |
| Average Diluted Shares Outstanding | 6.06M | 4.04M | 2.68M | 1.85M | 1.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |